title: Evolution of animal models in cancer vaccine development.
abstract: Advances in cancer vaccine development are facilitated by animal models reflecting key features of human cancer and its interface with host immunity. Several series of transplantable preneoplastic and neoplastic mouse mammary lesions have been used to delineate mechanisms of anti-tumor immunity. Mimicking immune tolerance to tumor-associated antigens (TAA) such as HER2/neu, transgenic mice developing spontaneous mammary tumors are strong model systems for pre-clinical vaccine testing. In these models, HER2 DNA vaccines are easily administered, well-tolerated, and induce both humoral and cellular immunity. Although engineered mouse strains have advanced cancer immunotherapy, basic shortcomings remain. For example, multiple mouse strains have to be tested to recapitulate genetic regulation of immune tolerance in humans. Outbred domestic felines more closely parallel humans in the natural development of HER2 positive breast cancer and their varying genetic background. Electrovaccination with heterologous HER2 DNA induces robust adaptive immune responses in cats. Importantly, homologous feline HER2 DNA with a single amino acid substitution elicits unique antibodies to feline mammary tumor cells, unlocking a new vaccine principle. As an alternative approach to targeted vaccination, non-surgical tumor ablation such as cryoablation induces anti-tumor immunity via in situ immunization, particularly when combined with toll-like receptor (TLR) agonist. As strategies for vaccination advance, non-invasive monitoring of host response becomes imperative. As an example, magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning following administration of tryptophan metabolism tracer [11C]-alpha-methyl-tryptophan (AMT) provides non-invasive imaging of both tumor growth and metabolic activities. Because AMT is a substrate of indoleamine-pyrrole 2,3-dioxygenase (IDO), an enzyme that produces the immune regulatory molecule kynurenine, AMT imaging can provide novel insight of host response. In conclusion, new feline models improve the predictive power of cancer immunotherapy and real-time PET imaging enables mechanistic monitoring of host immunity. Strategic utilization of these new tools will expedite cancer vaccine development.
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States. Electronic address: weiw@karmanos.org.
authors.forename: Wei-Zen
authors.initials: WZ
authors.lastname: Wei
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States.
authors.forename: Richard F
authors.initials: RF
authors.lastname: Jones
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States.
authors.forename: Csaba
authors.initials: C
authors.lastname: Juhasz
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States.
authors.forename: Heather
authors.initials: H
authors.lastname: Gibson
authors.affiliation: Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States.
authors.forename: Jesse
authors.initials: J
authors.lastname: Veenstra
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D002415:Cats; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*
chemical_list: D019496:Cancer Vaccines
keywords: Animal model; Cancer imaging; Cancer vaccine; DNA vaccine; Domestic cat; HER2/neu; In situ immunization; Transgenic mouse; Tumor ablation